Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy

Author(s): Deasmond O. Acheampong*, Christian K. Adokoh*, Paulina Ampomah, Daniel S. Agyirifor, Isaac Dadzie, Francis A. Ackah, Ernest A. Asiamah

Journal Name: Protein & Peptide Letters

Volume 24 , Issue 5 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and radiotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate perpetual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibodies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique characteristics. This review discusses up to date therapeutic potentials of BsAbs.

Keywords: Antibody, bispecific antibody (BsAb), immunotherapeutic agent, cancer therapy, diabody, antitumor.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [456 - 465]
Pages: 10
DOI: 10.2174/0929866524666170120095128
Price: $65

Article Metrics

PDF: 38